Atara Biotherapeutics, Inc.

NasdaqGS:ATRA Stock Report

Market Cap: US$83.4m

Atara Biotherapeutics Management

Management criteria checks 1/4

Atara Biotherapeutics' CEO is Cokey Nguyen, appointed in Sep 2024, has a tenure of 1.67 years. total yearly compensation is $1.07M, comprised of 62.6% salary and 37.4% bonuses, including company stock and options. directly owns 0.46% of the company’s shares, worth $386.89K. The average tenure of the management team and the board of directors is 1.3 years and 1.7 years respectively.

Key information

Cokey Nguyen

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage62.62%
CEO tenure1.7yrs
CEO ownership0.5%
Management average tenure1.3yrs
Board average tenure1.7yrs

Recent management updates

Recent updates

Analysis Article • Feb 16

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues

Atara Biotherapeutics, Inc.'s ( NASDAQ:ATRA ) price-to-sales (or "P/S") ratio of 0.2x might make it look like a strong...
Seeking Alpha • Nov 30

Atara Biotherapeutics: An Empty Pipeline With Little Gas

Summary Atara Biotherapeutics is on the precipice of being behind an FDA approval for a novel cell therapy. However, they do not hold the rights for this cell therapy's commercialization. Furthermore, ATRA has suspended development of their pipeline, meaning there are few, if any, catalysts to justify buying in. Read the full article on Seeking Alpha
Analysis Article • Oct 09

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 30% gain in the last...
Analysis Article • Aug 13

There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues Despite A 25% Share Price Rise

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 25% gain in the last...
Analysis Article • May 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders are no doubt pleased to see that the share price has bounced...
Analysis Article • May 01

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 07

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop

Unfortunately for some shareholders, the Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) share price has dived 27% in the...
Seeking Alpha • Jan 21

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Summary Atara has just announced a CRL by FDA for EBVALLO. EBVALLO is already approved in Europe since December 2022 and the cause of the CRL seems minor and easily addressable. The CRL has a major impact on cash runway, considering delay in milestone payments related to approval as well as future royalties. Nevertheless, ATRA remains eligible for these future payments. This forced ATRA to suspend its CAR-T pipeline in search for strategic alternatives. On the bright side, this creates another short-term catalyst and allows ATRA to focus resources on EBVALLO. ATRA estimates that available cash along a newly announced $15M equity line of credit are sufficient to fund operations through approval, but the risk of further cash raise is real. Read the full article on Seeking Alpha
Analysis Article • Jan 16

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares have continued their recent momentum with a 25% gain in the last...
Analysis Article • Jan 07

Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders have had their patience rewarded with a 34% share price jump...
Analysis Article • Sep 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Those holding Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares would be relieved that the share price has rebounded...
Analysis Article • Jul 21

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shareholders are no doubt pleased to see that the share price has bounced...
Seeking Alpha • Jul 03

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Summary Atara Biotherapeutics is a biotech company developing allogeneic EBV T cells for oncology and autoimmune indications, with a world-first allogeneic CAR-T approval in Europe and nearing FDA approval. Assuming no regulatory delays ATRA is well-funded to deliver proof-of-concept clinical data for its CAR-T platform in both B-cell malignancies and lupus, with an estimated cash runway into 2027. Despite fierce competition, ATRA's differentiated CAR-T platform combines all the best attributes of the competition, thus having a best-in-class potential. The major short-term risk is regulatory delays, meaning delays in pending regulatory milestone payments, which would likely necessitate a cash raise. Read the full article on Seeking Alpha
Analysis Article • May 14

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Shareholders in Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) may be thrilled to learn that the analysts have just...
Analysis Article • May 11

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

To the annoyance of some shareholders, Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) shares are down a considerable 26...
Seeking Alpha • Feb 06

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Summary Atara Biotherapeutics is a biotech company focused on developing cell therapies for Epstein-Barr virus infection and cancer. Their most advanced product, tab-cel, has shown promising results in treating EBV-associated post-transplant lymphoproliferative disease. The company's financial situation is uncertain, but recent partnerships and potential revenue growth from tab-cel could improve their cash runway. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Cokey Nguyen's remuneration changed compared to Atara Biotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$9m

Dec 31 2025US$1mUS$669k

US$33m

Sep 30 2025n/an/a

US$23m

Jun 30 2025n/an/a

US$6m

Mar 31 2025n/an/a

-US$16m

Dec 31 2024US$2mUS$586k

-US$85m

Sep 30 2024n/an/a

-US$133m

Jun 30 2024n/an/a

-US$181m

Mar 31 2024n/an/a

-US$233m

Dec 31 2023US$2mUS$540k

-US$276m

Compensation vs Market: Cokey's total compensation ($USD1.07M) is above average for companies of similar size in the US market ($USD627.03K).

Compensation vs Earnings: Cokey's compensation has been consistent with company performance over the past year.

CEO

Cokey Nguyen (52 yo)

1.7yrs
Tenure
US$1,068,069
Compensation

Dr. Anhco Nguyen, Ph D., also known as Cokey, has been the President, Chief Executive Officer and Director of Atara Biotherapeutics Inc. since September 09, 2024. He served as Chief Scientific Officer at A...

Leadership Team

NamePositionTenureCompensationOwnership
Anhco Nguyen
President1.7yrsUS$1.07m0.46%
$ 386.9k
Yanina Grant-Huerta
Chief Accounting Officer & Principal Accounting Officer1.2yrsno data0.20%
$ 166.6k
Alex Chapman
Vice President of Corporate Communications & Investor Relationsno datano datano data
John Chao
Head of Legal1.5yrsno datano data
Jim Sesic
Senior Vice President of Regulatory Affairs1yrno datano data
1.3yrs
Average Tenure

Experienced Management: ATRA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Anhco Nguyen
President1.7yrsUS$1.07m0.46%
$ 386.9k
Zuie-Chin Huang
Independent Director1yrno datano data
William Heiden
Independent Director10.5yrsUS$141.39k0.17%
$ 140.7k
Matthew Fust
Independent Director12.2yrsUS$136.39k0.12%
$ 101.5k
Carol Gallagher
Independent Director13.3yrsUS$146.69k0.30%
$ 246.8k
Gregory Ciongoli
Independent Chairman1.7yrsno datano data
Nachi Subramanian
Independent Director1yrno datano data
1.7yrs
Average Tenure
59.5yo
Average Age

Experienced Board: ATRA's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/24 05:36
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atara Biotherapeutics, Inc. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Yigal NochomovitzCitigroup Inc
Michael KingCitizens JMP Securities, LLC